Table of Contents Author Guidelines Submit a Manuscript
Schizophrenia Research and Treatment
Volume 2019, Article ID 5094017, 9 pages
https://doi.org/10.1155/2019/5094017
Research Article

Attitude towards Antipsychotic Medications in Patients Diagnosed with Schizophrenia: A Cross-Sectional Study at Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia

1Department of Psychiatry, University of Gondar, Gondar, Ethiopia
2Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia
3Department of Emergency and Critical Care Nursing, University of Gondar, Gondar, Ethiopia

Correspondence should be addressed to Shegaye Shumet; moc.oohay@eyagehstemuhs

Received 29 January 2019; Revised 6 April 2019; Accepted 15 May 2019; Published 22 May 2019

Academic Editor: Hugo Schnack

Copyright © 2019 Tilahun Kassew et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Tandon, W. Gaebel, D. M. Barch et al., “Definition and description of schizophrenia in the DSM-5,” Schizophrenia Research, vol. 150, no. 1, pp. 3–10, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. J. DiPiro, L. Robert, C. Gary, G. Barbara, and L. Posy, Pharmacotherapy, A Pathophysiologic Approach, McGraw - Hill, New York, NY, USA, 9th edition, 2014.
  3. D. Kasper, A. Fauci, S. Hauser, D. Longo, J. Jameson, and J. Loscalzo, Harrison's Principles of Internal Medicine, vol. 19e, 2015.
  4. R. E. Nielsen, E. Lindström, J. Nielsen, and S. Levander, “DAI-10 is as good as DAI-30 in schizophrenia,” European Neuropsychopharmacology, vol. 22, no. 10, pp. 747–750, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. M. S. Karthik, N. Warikoo, S. Chakrabarti, S. Grover, and P. Kulhara, “Attitudes towards antipsychotics among patients with schizophrenia on first- or second-generation medications,” Indian Journal of Psychological Medicine, vol. 36, no. 3, pp. 288–293, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. J. M. Kirigia and L. M. Sambo, “Cost of mental and behavioural disorders in Kenya,” Annals of General Psychiatry, vol. 2, no. 1, p. 7, 2003. View at Google Scholar · View at Scopus
  7. S. C. Burton, “Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use,” Journal of Psychiatric Practice, vol. 11, no. 6, pp. 369–378, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Kuroda, S. Sun, C.-K. Lin et al., “Attitudes toward taking medication among outpatients with schizophrenia: Cross-national comparison between Tokyo and Beijing,” Environmental Health and Preventive Medicine, vol. 13, no. 5, pp. 288–295, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. E. O. Katayi, Impact of Side Effects of Antipsychotics on Attitude and Adherence to Treatment among Adult Psychiatric Outpatients at Mathari Hospital in Kenya, School of Pharmacy, University of Nairobi, 2014.
  10. M. Sajatovic, F. DiBiasi, and S. N. Legacy, “Attitudes toward antipsychotic treatment among patients with bipolar disorders and their clinicians: a systematic review,” Neuropsychiatric Disease and Treatment, vol. 13, pp. 2285–2296, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. J. H. Effiong and K. A. Umoh, “Medication non adherence in schizophrenia: prevalence and correlates among outpatients in a tertiary healthcare facility in Uyo, South-South Nigeria,” Clinical Medicine and Diagnostics, vol. 5, no. 6, pp. 107–113, 2015. View at Google Scholar
  12. S. X. Sun, G. G. Liu, D. B. Christensen, and A. Z. Fu, “Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States,” Current Medical Research and Opinion, vol. 23, no. 10, pp. 2305–2312, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Teferra, T. Shibre, A. Fekadu et al., “Five-year clinical course and outcome of schizophrenia in Ethiopia,” Schizophrenia Research, vol. 136, no. 1-3, pp. 137–142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Teferra, T. Shibre, A. Fekadu et al., “Five-year mortality in a cohort of people with schizophrenia in Ethiopia,” BMC Psychiatry, vol. 11, no. 1, p. 165, 2011. View at Google Scholar · View at Scopus
  15. D. V. Jeste, J. A. Gladsjo, L. A. Lindamer, and J. P. Lacro, “Medical comorbidity in schizophrenia,” Schizophrenia Bulletin, vol. 22, no. 3, pp. 413–430, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Haddad, C. Brain, and J. Scott, “Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies,” Patient Related Outcome Measures, vol. 5, p. 43, 2014. View at Publisher · View at Google Scholar
  17. K. C. Terkelsen and A. Menikoff, “Measuring the costs of schizophrenia: implications for the post-institutional era in the US,” PharmacoEconomics, vol. 8, no. 3, pp. 199–222, 1995. View at Publisher · View at Google Scholar · View at Scopus
  18. I. S. Chandra, K. L. Kumar, M. P. Reddy, and C. M. P. K. Reddy, “Attitudes toward medication and reasons for non-compliance in patients with schizophrenia,” Indian Journal of Psychological Medicine, vol. 36, no. 3, pp. 294–298, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Caqueo-Urízar, A. Urzúa, G. Fond, and L. Boyer, “Medication nonadherence among South American patients with schizophrenia,” Patient Preference and Adherence, vol. 11, pp. 1737–1744, 2017. View at Publisher · View at Google Scholar · View at Scopus
  20. A. O. Adewuya, B. A. Ola, S. K. Mosaku, F. O. Fatoye, and A. B. Eegunranti, “Attitude towards antipsychotics among out-patients with schizophrenia in Nigeria,” Acta Psychiatrica Scandinavica, vol. 113, no. 3, pp. 207–211, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Hofer, M. A. Rettenbacher, M. Edlinger, G. Kemmler, C. G. Widschwendter, and W. W. Fleischhacker, “Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia,” Acta Psychiatrica Scandinavica, vol. 116, no. 5, pp. 354–361, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. R. G. S. Baby and Sagar R., “Attitudes and subjective reasons of medication compliance and noncompliance among outpatients with schizophrenia in India,” The Internet Journal of Epidemiology, vol. 7, no. 1, 2009. View at Google Scholar
  23. A. Hofer, S. Baumgartner, M. Edlinger et al., “Patient outcomes in schizophrenia I: Correlates with sociodemographic variables, psychopathology, and side effects,” European Psychiatry, vol. 20, no. 5-6, pp. 386–394, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. I. V. Vassileva and V. K. Milanova, “Attitudes toward antipsychotic medication, insight and psychopathology in outpatients with schizophrenia.,” Folia Medica, vol. 54, no. 4, pp. 62–68, 2012. View at Google Scholar · View at Scopus
  25. P. Rocca, B. Crivelli, F. Marino, T. Mongini, F. Portaleone, and F. Bogetto, “Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia,” Comprehensive Psychiatry, vol. 49, no. 2, pp. 170–176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. J. C. Day, R. P. Bentall, C. Roberts et al., “Attitudes toward antipsychotic medication: The impact of clinical variables and relationships with health professionals,” Archives of General Psychiatry, vol. 62, no. 7, pp. 717–724, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Mohamed, R. Rosenheck, J. McEvoy, M. Swartz, S. Stroup, and J. A. Lieberman, “Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia,” Schizophrenia Bulletin, vol. 35, no. 2, pp. 336–346, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. A. O. Adewuya, O. A. Owoeye, A. R. Erinfolami et al., “Prevalence and correlates of poor medication adherence amongst psychiatric outpatients in southwestern Nigeria,” General Hospital Psychiatry, vol. 31, no. 2, pp. 167–174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. P. N. Mahadun and M. Marshall, “Insight and treatment attitude in schizophrenia: Comparison of patients on depot and atypical antipsychotics,” Psychiatric Bulletin, vol. 32, no. 2, pp. 53–56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Lambert, P. Conus, P. Eide et al., “Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence,” European Psychiatry, vol. 19, no. 7, pp. 415–422, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. M. A. Rettenbacher, A. Hofer, U. Eder et al., “Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication,” Journal of Clinical Psychiatry, vol. 65, no. 9, pp. 1211–1218, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. O. Freudenreich, C. Cather, A. E. Evins, D. C. Henderson, and D. C. Goff, “Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight,” Journal of Clinical Psychiatry, vol. 65, no. 10, pp. 1372–1376, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. H. C. Margolese, L. Malchy, J. C. Negrete, R. Tempier, and K. Gill, “Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences,” Schizophrenia Research, vol. 67, no. 2-3, pp. 157–166, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. P. A. Ringen, I. Melle, A. B. Birkenaes et al., “Illicit drug use in patients with psychotic disorders compared with that in the general population: a cross-sectional study,” Acta Psychiatrica Scandinavica, vol. 117, no. 2, pp. 133–138, 2008. View at Publisher · View at Google Scholar
  35. S. R. Kay, A. Fiszbein, and L. A. Opler, “The positive and negative syndrome scale (PANSS) for schizophrenia,” Schizophrenia Bulletin, vol. 13, no. 2, pp. 261–276, 1987. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Birchwood, J. Smith, V. Drury, J. Healy, F. Macmillan, and M. Slade, “A self‐report Insight Scale for psychosis: reliability, validity and sensitivity to change,” Acta Psychiatrica Scandinavica, vol. 89, no. 1, pp. 62–67, 1994. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Waddell and M. Taylor, “A new self-rating scale for detecting atypical or second-generation antipsychotic side effects,” Journal of Psychopharmacology, vol. 22, no. 3, pp. 238–243, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Loga-Zec and S. Loga, “Antipsychotics and the quality of life of schizophrenic patients,” Psychiatria Danubina, vol. 22, no. 4, pp. 495–497, 2010. View at Google Scholar · View at Scopus
  39. E. Medina, J. Salvà, R. Ampudia, J. Maurino, and J. Larumbe, “Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder,” Patient Preference and Adherence, vol. 6, pp. 623–629, 2012. View at Google Scholar · View at Scopus
  40. J. Yang, Y.-H. Ko, J.-W. Paik et al., “Symptom severity and attitudes toward medication: Impacts on adherence in outpatients with schizophrenia,” Schizophrenia Research, vol. 134, no. 2-3, pp. 226–231, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Naber, A. Karow, and M. Lambert, “Subjective well-being under neuroleptic treatment and its relevance for compliance,” Acta Psychiatrica Scandinavica, Supplement, vol. 111, no. 427, pp. 29–34, 2005. View at Google Scholar · View at Scopus
  42. A. Karow, D. Schnedler, and D. Naber, “What would the patient choose? Subjective comparison of atypical and typical neuroleptics,” Pharmacopsychiatry, vol. 39, no. 2, pp. 47–51, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Voruganti, L. Cortese, L. Owyeumi et al., “Switching from conventional to novel antipsychotic drugs: Results of a prospective naturalistic study,” Schizophrenia Research, vol. 57, no. 2-3, pp. 201–208, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Hofer, G. Kemmler, U. Eder, M. Honeder, M. Hummer, and W. W. Fleischhacker, “Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia,” Journal of Clinical Psychiatry, vol. 63, no. 1, pp. 49–53, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. R. Baby, S. Gupta, and R. Sagar, “Attitudes and subjective reasons of medication compliance and noncompliance among outpatients with schizophrenia,” The Internet Journal of Epidemiology, vol. 7, no. 1, 2008. View at Google Scholar
  46. R. J. Wyat, “Neuroleptics and the natural course of schizophrenia,” Schizophrenia Bulletin, vol. 17, no. 2, pp. 325–351, 1991. View at Publisher · View at Google Scholar · View at Scopus